<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30376085</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>suppl_1</Issue><PubDate><Year>2018</Year><Month>Oct</Month><Day>30</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>OPV Vaccination and Shedding Patterns in Mexican and US Children.</ArticleTitle><Pagination><StartPage>S85</StartPage><EndPage>S89</EndPage><MedlinePgn>S85-S89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciy636</ELocationID><Abstract><AbstractText Label="BACKGROUND">As wild poliovirus is eradicated and countries switch from oral poliovirus vaccine (OPV) to inactivated poliovirus vaccine (IPV) per World Health Organization recommendations, preventing circulation of vaccine-derived poliovirus (cVDPV) is a top priority. Currently, the impact of prior poliovirus vaccination on OPV shedding is not fully understood.</AbstractText><AbstractText Label="METHODS">Stool samples from 2 populations were tested for OPV to assess shedding patterns. 505 samples from 43 US children vaccinated with OPV were collected over 42 days post-vaccination. 1,379 samples from 148 Mexican children vaccinated with OPV were collected over 71 days post-vaccination. Prior vaccination history was recorded for both groups.</AbstractText><AbstractText Label="RESULTS">Seventeen (40%) of the US children had never received poliovirus vaccination while the Mexican children had received at least 2 doses of IPV and 116 (78%) had OPV exposure. In total, 84% of US children and 78% of Mexican children shed OPV (P = .44, Fisher exact test), with a mean shedding duration of 17.4 days for US children and 9.3 days for Mexican children (P &lt; .0001, Wilcoxon-Mann Whitney test).</AbstractText><AbstractText Label="CONCLUSIONS">Prior vaccination did not affect the likelihood of shedding, as the US and Mexico cohorts had similar shedding proportions. However, prior vaccination affected shedding duration as the Mexican children, who were largely OPV exposed and all of whom had at least 2 IPV vaccinations, shed OPV for half as long as the US cohort. Since different countries maintain different poliovirus vaccination schedules, it is likely that duration of shedding of OPV varies in populations around the world.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altamirano</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarnquist</LastName><ForeName>Clea</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behl</LastName><ForeName>Rasika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Garc&#xed;a</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Salud P&#xfa;blica, Cuernavaca, Morelos, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreyra-Reyes</LastName><ForeName>Leticia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Salud P&#xfa;blica, Cuernavaca, Morelos, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leary</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017201" MajorTopicYN="N">Virus Shedding</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30376085</ArticleId><ArticleId IdType="pmc">PMC6206113</ArticleId><ArticleId IdType="doi">10.1093/cid/ciy636</ArticleId><ArticleId IdType="pii">5146682</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Polio Eradication Initiative: annual report 2016. Geneva, Switzerland: World Health Organization, 2017. (WHO/Polio/17.03). Licence: CC BY-NC-SA 3.0 IGO.</Citation></Reference><Reference><Citation>
World Health Organization. Polio Global Eradication Initiative
2017.  [Online]. Available at: http://polioeradication.org/polio-today/polio-now/. Accessed 31 December 2017.</Citation></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. ; Immunization Systems Management Group of the Global Polio Eradication Initiative Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine&#x2014;worldwide, 2016. MMWR Morb Mortal Wkly Rep 2016; 65:934&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Okayasu H, Sutter RW, Czerkinsky C, Ogra PL. Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine 2011; 29:8205&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">21896299</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt LR, Est&#xed;variz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014; 210(Suppl 1):S380&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis 2014; 210(Suppl 1):S283&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. Polio Eradication &amp; Endgame Strategic Plan 2013&#x2013;2018
2013.  [Online]. Available at: http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_US.pdf. Accessed 16 November 2017.</Citation></Reference><Reference><Citation>
World Health Organization. OPV [Online]. Available at: http://polioeradication.org/polio-today/polio-prevention/the-vaccines/opv/. Accessed 16 August 2017.</Citation></Reference><Reference><Citation>Troy SB, Musingwini G, Halpern MS, et al. . Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants. J Infect Dis 2013; 208:672&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719901</ArticleId><ArticleId IdType="pubmed">23661792</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC, Jafari H, Bahl S, et al. . Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis 2009; 200:794&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19624278</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries review. Rev Infect Dis 1991; 13:926&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathogens 2012; 8:e1002599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis 2014; 210(Suppl 1):S439&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197908</ArticleId><ArticleId IdType="pubmed">24634499</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker EP, Molodecky NA, Pons-Salort M, O'Reilly KM, Grassly NC. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. Expert Rev Vaccines 2015; 14:1113&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4673562</ArticleId><ArticleId IdType="pubmed">26159938</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarnquist C, Holubar M, Garcia-Garcia L, et al. Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization. Clin Infect Dis. 2018; 67(S1):S114&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206104</ArticleId><ArticleId IdType="pubmed">30376084</ArticleId></ArticleIdList></Reference><Reference><Citation>Altamirano J, Purington N, Behl R, et al. Characterization of Household and Community Shedding and Transmission of Oral Polio Vaccine in Mexican Communities With Varying Vaccination Coverage. Clin Infect Dis 2018; 67(S1):S3&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206120</ArticleId><ArticleId IdType="pubmed">30376097</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez C, Old MO, Kwock DK, et al. . Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. J Infect Dis 2004; 190:409&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15216480</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoorebeke C, Huang C, Leary S, et al. Lab Protocol Paper: Use of a High-throughput, Multiplex Reverse-transcription Quantitative Polymerase Chain Reaction Assay for Detection of Sabin Oral Polio Vaccine in Fecal Samples. Clin Infect Dis. 2018; 67(S1):S120&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206103</ArticleId><ArticleId IdType="pubmed">30376092</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>